TruScreen Signs MOU with Hangzhou Dalton Bioscience

NZX/ASX Announcement

27 February 2025

TruScreen Signs MOU with Hangzhou Dalton Bioscience
to Expand its HPV Product Offerings

• TruScreen Group Limited has signed a non-binding Memorandum of Understanding (“MOU”) with Hangzhou Dalton Bioscience Limited (“DaltonBio”), a leading China based manufacturer of high-performance HPV DNA tests and laboratory equipment for cervical cancer screening.
• The MOU provides a framework for collaboration to distribute, and marketing of complementary HPV related In Vitro Diagnostics (“IVD”) products through the selected TruScreen global distribution network, under the TruScreen brand.
• The MOU supports TruScreen’s strategy to expand its HPV related product portfolio that strengthens its global position in the women’s health sector.


TruScreen Group Limited (NZX/ASX: TRU), (“TruScreen” or “the Company”), a global leader in AI-enabled cervical cancer screening, is pleased to announce that it has signed a non-binding MOU with DaltonBio, a leading China based manufacturer of high-performance HPV DNA tests and laboratory equipment for cervical cancer screening, to expand global commercial opportunities for a suite of DaltonBio’s HPV related IVD products to be marketed under the TruScreen brand.

The collaboration will enhance access to innovative cervical cancer screening and detection solutions by leveraging the technology strengths of both companies.

Pursuant to the MOU, TruScreen and DaltonBio will negotiate to formalise a distribution agreement within three months from the date of the MOU. The proposed collaboration consists of two key stages:

1. Short-Term Collaboration: TruScreen will conduct due diligence on DaltonBio’s HPV related IVD products, namely HPV DNA tests, and self-sampling tests for marketing through TruScreen’s selected global distribution network.

2. Medium-to-Long-Term Strategic Alliance: Subject to a successful stage 1 collaboration, TruScreen to be appointed a global distributor of DaltonBio HPV related IVD products (excluding U.S.A. and Canada). DaltonBio to explore opportunities to assist TruScreen’s AI enabled real time cervical screening device within its distribution network, notably in its selected distributors in China and South America.

TruScreen CEO, Marty Dillon commented: "This collaboration is a significant step forward in our mission to provide innovative and accessible cervical cancer screening solutions worldwide. Dalton BioSciences HPV screening tests complement TruScreen’s AI enabled real-time cervical screening technology. This will enable TruScreen to offer a range of comprehensive solutions to healthcare providers globally. We are excited about the potential of this partnership and look forward to progressing towards a formal distribution agreement."



DaltonBio Founder and President, Dr. Ben Hua commented: "Both DaltonBio HPV tests and TruScreen AI enabled screening worked in conjunction with each other as a triage to confirm the positive result of a patient, prior to treatment for HPV cancerous lesions. This collaboration is a natural extension of both companies’ technologies to offer best available solutions to healthcare clinicians globally. Our cost-effective high-performance HPV DNA tests and other IVD products for women’s health are ideally suited for use in many countries where TruScreen has distribution. We look forward to progressing towards a formal distribution agreement for TruScreen."

TruScreen was advised by the Sydney team of Hong Kong headquartered Innokylin Capital Limited .

This announcement has been approved by the Board.

Ends


For more information, visit www.truscreen.com or contact:
Martin Dillon
Chief Executive Officer
[email protected]

Guy Robertson
Chief Financial Officer
[email protected]

---

Announcement PDF